ACADEMY OF MANAGED CARE PHARMACY for ACADEMY OF MANAGED CARE PHARMACY
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Increased funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing, appropriations for the U.S. Food and Drug Administration
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Labor Issues/Antitrust/Workplace LBR
Granting independent pharmacists collective bargaining rights/antitrust exemption
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Medicare/Medicaid MMM
Proposed changes to the Medicare Part D prescription drug benefit: modifying current Part D prompt payment rules for pharmacies in order to better combat fraud, waste and abuse; legislation that would expand the current medication therapy management program in Part D (S 274/HR 891)
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Pharmacy PHA
Legislation relating to pharmacy issues and the professional role of pharmacists, legislation relating to medication therapy management programs and funding for such programs, legislation relating to the importation of prescription drugs, legislation relating to settlement agreements between brand-name and generic manufacturers, legislation promoting the use of generic drugs generally, legislation relating to pharmacy benefit managers
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.